S. Cure

发表

Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis

E. Jones, S. Cure, J. Diels, 2012, Current medical research and opinion.

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients

G. Dusheiko, Seina P. Lee, S. Cure, 2014, Journal of medical economics.

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients

G. Dusheiko, Seina P. Lee, S. Cure, 2014, Journal of medical economics.

Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018

L. Pezzullo, E. Tsochatzis, P. Newsome, 2021, The European Journal of Health Economics.

Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens

H. Hardy, T. Juday, C. Espinas, 2015, PloS one.

Cost–utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan

A. Igarashi, Lucile Marié, S. Cure, 2017, Current medical research and opinion.

Cost-Effectiveness of Apremilast In Psoriatic Arthritis In Scotland.

T. Tencer, S. Cure, F. Zhang, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

PIN7 The Comparative Efficacy of Telaprevir Versus Boceprevir in Treatment-Naive and Treatment-Experienced Patients with Genotype 1 Chronic Hepatitis

S. Cure, J. Diels, S. Gavart, 2011 .

Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis

V. de Lédinghen, J. Lazarus, L. Pezzullo, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events

C. Canivet, J. Ampuero, M. Bonacci, 2022, Journal of Hepatology.

Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands

G. Berdeaux, M. Lamotte, M. Agthoven, 2014, Applied Health Economics and Health Policy.

Cost–utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan

Kiichiro Tsutani, K. Tsutani, A. Igarashi, 2017, Current medical research and opinion.

Cost‐effectiveness of sofosbuvir for the treatment of chronic hepatitis C‐infected patients

G. Dusheiko, S. Cure, I. Guerra, 2015, Journal of viral hepatitis.

Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom.

A. Young, N. Danchenko, S. Cure, 2017, Journal of affective disorders.

Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland

K. Kolasa, N. Danchenko, H. Koponen, 2017, Expert review of pharmacoeconomics & outcomes research.

Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens

R. Sheldon, S. Aballéa, J. Chancellor, 2012, PharmacoEconomics.

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy

G. Carosi, A. Craxì, S. Cure, 2015, Journal of medical economics.

Cost-Effectiveness and Long-Term Outcomes of Sovaldi (SOFOSBUVIR) for the Treatment of Chronic Hepatitis C Infected (HCV) Patients from a Swedish Societal Perspective.

S. Cure, I. Guerra, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Systematic literature review and meta-analysis of diagnostic test accuracy in Alzheimer's disease and other dementia using autopsy as standard of truth.

Keith Abrams, Mark Belger, Michael Happich, 2014, Journal of Alzheimer's disease : JAD.

Cost‐effectiveness of highly purified omega‐3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting

L. Tavazzi, A. Mcguire, M. Cowie, 2011, European journal of heart failure.

Chronic insomnia, quality-of-life, and utility scores: comparison with good sleepers in a cross-sectional international survey.

D. Léger, C. Morin, M. Uchiyama, 2012, Sleep medicine.

Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C

F. Negro, D. Lavanchy, B. Müllhaupt, 2015, PloS one.

THU0448 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab Up To 48 Weeks Using A Matching-Adjusted Indirect Comparison

P. Mease, I. McInnes, H. Thom, 2016 .

The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries

V. de Lédinghen, V. Atella, A. Torbica, 2020, Zeitschrift für Gastroenterologie - German Journal of Gastroenterology.

Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C

F. Negro, D. Lavanchy, B. Müllhaupt, 2015, PloS one.

Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom.

S. Cure, R. Campbell, M. Brignone, 2017, Journal of affective disorders.

A New Citrated Formulation of Nalidixic Acid (Mictral® U.K.) for the Treatment of Acute Cystitis

S. Cure, C. Dulake, F. Allenby, 1981, The Journal of international medical research.

Cost‐effectiveness of highly purified omega‐3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting

L. Tavazzi, A. Mcguire, M. Cowie, 2011, European journal of heart failure.

Long-Term Outcomes of Ledipasvir/Sofosbuvir (LDV/ SOF) for the Treatment of Chronic Hepatitis C Infected (HCV) Genotype 1 Patients in the UK.

S. Cure, I. Guerra, L. Marié, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.